I assume Avita one is class II resubmission with minimal effort fix it and it will get the approval in anytime from now, if shorts playing, that’s going to be a loose for them…
- Class I resubmissions: If the FDA determines that additional information or data from the sponsor can easily address minor deficiencies in their application, it is classified as a class 1 resubmission. Upon resubmission, the FDA has two to three months to review these applications.
- Class II resubmissions: If the FDA determines that significant changes or new data are needed to address sponsor deficiencies in their application, it is classified as a class 2 resubmission. Upon resubmission, the FDA has six months to review these applications.
Ann: AVITA Medical to Announce First Quarter 2024 Results, page-6
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.60 |
Change
-0.120(4.41%) |
Mkt cap ! $172.4M | |||
| Open | High | Low | Value | Volume |
| $2.68 | $2.68 | $2.60 | $916.1K | 346.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3160 | $2.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.63 | 300 | 1 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$2.62 |
Change
-0.120 ( 3.96 %) |
||||
| Open | High | Low | Volume | ||
| $2.65 | $2.66 | $2.60 | 40085 | ||
| Last updated 15.55pm 14/06/2024 ? | |||||
| AVH (ASX) Chart |